Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 58Breast Neoplasms 43Prostatic Neoplasms 32Lung Neoplasms 29Multiple Myeloma 23Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 17Ovarian Neoplasms 17Colorectal Neoplasms 17Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Carcinoma, Renal Cell 14Pancreatic Neoplasms 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Myasthenia Gravis 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5

Interventions

pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2azathiopurine 2auricularum 2Vincristine 2Thioguanine 2Methotrexate 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2Cytarabine 2Cyclophosphamide 2Calcium Dobesilate 2prednylidene 1deltacortene 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methylprednisolone 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Down Syndrome × 30 days × Clear all
NCT01190930 2026-05-28

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡